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Abstract
To investigate the functional effects of resveratrol (RSV) on mesenchymal stem cells (MSCs), we treated MSCs with RSV
continuously during ex vivo expansion. MSCs were continuously treated with RSV from passage (P) 0 to P5. A
proliferative capacity of RSV-treated MSCs was higher than that of non-treated MSCs and similar with P1-MSCs.
Continuous treatment of RSV on MSCs increased the stemness and inhibited the senescence. During chondrogenic
differentiation in vitro, RSV-treated MSCs had higher differentiation potential and reduced hypertrophic maturation,
which are limitations for hyaline cartilage formation. The histological analysis of micromass demonstrated increased
chondrogenic differentiation potential. We further explored the therapeutic effectiveness of this method in a rabbit
osteochondral defect model. A rabbit osteochondral defect model was established to investigate the hyaline cartilage
regeneration potential of RSV-treated MSCs. Moreover, the cartilage regeneration potential of RSV-treated MSCs was
greater than that of untreated MSCs. The expression levels of chondrogenic markers increased and those of
hypertrophic markers decreased in RSV-treated MSCs compared with untreated MSCs. Sustained treatment of RSV on
MSCs during ex vivo expansion resulted in the maintenance of stemness and enhanced chondrogenic differentiation
potential. Consequentially, highly efﬁcient MSCs promoted superior hyaline cartilage regeneration in vivo. This novel
treatment method provides a basis for cell-based tissue engineering.
Introduction
Osteoarthritis (OA) involves cartilage damage, dys-
functional chondrocyte proliferation, and hypertrophic
maturation1–4. Several types of therapies are currently
used for cartilage regeneration, including bone marrow-
stimulating techniques, mosaicplasty, and cell-based
therapies5. Cell-based therapies are increasingly used as
a prospective treatment. Autologous chondrocyte
implantation is commonly used for cartilage regeneration,
requiring the in vitro expansion of autologous
chondrocytes6. Nevertheless, these techniques have sev-
eral shortcomings, such as their complexity, cost, and the
loss of cartilage capacity7,8. Therefore, cell-based ther-
apeutic approaches using mesenchymal stem cells (MSCs)
have emerged for cartilage regeneration9–11.
MSCs have various advantages for clinical applications,
such as anti-inﬂammatory and immunosuppressive
effects, high effectiveness, and a lack of severe side
effects12. Additionally, MSCs possess a high stemness
capacity and thereby have the potential for multipotency,
including chondrogenic differentiation. For these reasons,
MSCs are a promising cell source for cartilage regenera-
tion13–15. However, several factors limit the clinical
application of MSCs. For example, hundreds of millions of
MSCs are required. MSCs can be isolated from various
organs, but the number of isolated cells is insufﬁcient. To
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obtain sufﬁcient MSCs, long-term in vitro expansion is
necessary16; however, acquiring an effective quantity of
MSCs with sustained self-renewal and multi-lineage dif-
ferentiation potential is difﬁcult17,18. Moreover, MSCs
tend to become ﬁbro-like tissues after the induction of
chondrogenic differentiation19,20, and they exhibit ﬁbro-
like tissue regeneration in vivo. Therefore, the identiﬁca-
tion of new environments for the development of highly
efﬁcient MSCs with an enhanced self-renewal capacity
and chondrogenic differentiation potential is necessary.
Mohyeldin et al.21 demonstrated that MSCs require
physiological oxygen levels of between 2 and 8%. Under
hypoxic conditions, the expression levels of hypoxia-
inducible factors increase, leading to the upregulation of
Oct-4, Sox2, and Nanog, which are critical transcription
factor for stemness22. Previous studies have suggested that
under hypoxic conditions, MSCs have enhanced pro-
liferative potential and stemness during in vitro cultiva-
tion23. In fact, antioxidants, such as resveratrol24, palm
vitamin E25, butylated hydroxyanisole26, and butylated
hydroxytoluene27, are known to not only suppress reac-
tive oxygen species, but also delay disease progression and
inﬂuence lipid peroxidation28. Butylated hydroxyanisole
and butylated hydroxytoluene are frequently used as
additives in the food industry26,29; however, their use is
restricted owing to their potential toxicity and carcino-
genic effects28. Thus, the discovery of new, safe anti-
oxidants that can overcome the disadvantages of chemical
antioxidants is necessary.
The antioxidant resveratrol (RSV; 3,5,4ʹ-hydro-
xystilbene), a natural compound, is a phytoalexin pro-
duced by plants in response to environmental stress30–32.
RSV has critical roles in the inhibition of oxidative
damage33 as well as in cell survival and proliferation34–36.
Furthermore, RSV is known to enhance activity of sirtuin
1 (SIRT1), an NAD+-dependent lysine deacetylase. Dur-
ing in vitro cultivation, MSCs occasionally become
senescent, leading to a loss of stemness. Previously, Yuan
et al.35 demonstrated that the knockdown of SIRT1 in
early-passage MSCs using shRNA results in a loss of
proliferative capacity and promotes cellular senescence. In
contrast, the overexpression of SIRT1 in MSCs delays
cellular senescence and cells maintain multipotency dur-
ing long-term in vitro cultivation35. Moreover, RSV
enhances the osteogenic and adipogenic differentiation
potential of MSCs, but prolonged treatment of MSCs with
RSV induces senescence37,38. Other studies have demon-
strated that RSV has negative effects on MSCs during
adipogenic and osteogenic differentiation39,40. These
incompatible results regarding the effects of RSV on
senescence and differentiation in MSCs may be explained
by dose- or duration-dependent effects34. Hence, a novel
RSV treatment method for MSCs is necessary. Addi-
tionally, the effect of RSV on chondrogenic differentiation
has not been elucidated. In this study, we developed a
novel treatment method using RSV that yields consistent
results. Moreover, we evaluated the stemness and chon-
drogenic differentiation potential of MSCs after treatment
with RSV. This novel treatment method provides a basis
for cell-based tissue engineering.
Results
Increased stemness and decreased senescence of RSV-
treated MSCs
During in vitro cultivation, we continuously treated
MSCs with RSV from P0 to P5 (P5-RMSC), and other
cells were cultured up to P5 without RSV treatment (P5-
MSC) (Fig. 1a). To investigate whether RSV treatment
increases the self-renewal capacity of MSCs, we evaluated
the cell morphology and proliferative potential. P5-
RMSCs had a similar morphology to that of P1-MSCs,
i.e., cells were small and spindle-shaped. However, P5-
MSCs had a large, ﬂat appearance (Fig. 1b). P5-MSCs had
a decreased proliferative capacity over time, whereas the
P5-RMSCs had a similar proliferative capacity to that of
P1-MSCs (Fig. 1c). To determine the effects of RSV on
senescence and stemness, we assessed protein expression
levels of senescence and stemness markers such as P16,
P21, P53 and Nanog, Oct4, Sox2, respectively. In P5-
RMSCs, the stemness markers were up-regulated and
senescence markers were down-regulated, similar to the
expression levels in P1-MSCs, however, the opposite
results were obtained for P5-MSCs, which exhibited the
upregulation of senescence markers and down-regulation
of stemness markers (Fig. 1d, e). Therefore, continuous
treatment of RSV on MSCs was able to maintain the
stemness and inhibit senescence, suggesting that it is a
useful method for the establishment of highly efﬁcient
MSCs.
Enhancement of the chondrogenic differentiation
potential in RSV-treated MSCs
To evaluate the chondrogenic differentiation potential,
we performed micromass culture using P1-MSC, P5-
MSC, and P5-RMSC. The mRNA levels of Sox-5, -6, -9,
Col2a1, and aggrecan, which are chondrogenic markers,
were higher in P5-RMSC than in P5-MSC and were
similar to the levels in P1-MSC (Fig. 2a). The protein
expression levels of chondrogenic markers were com-
parable in P1-MSC and P5-RMSC and a quantitative
analysis supported this ﬁnding (Fig. 2b, c). To further
demonstrate the increased chondrogenic differentiation
potential of P5-RMSC, we performed SafO and AB
staining. The P5-MSC group had a much smaller micro-
mass size than those of the P1-MSC and P5-RMSC
groups, which both had higher contents of glycosami-
noglycan (GAG) and proteoglycan (PG) (Fig. 3a). We
evaluated the expression levels of col2a1 and aggrecan in
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micromass pellets by immunocytochemistry. P5-RMSC
had high expression levels of col2a1 and aggrecan, similar
to the expression levels in P1-MSC (Fig. 3b, c).
Accordingly, P5-RMSC, which had enhanced stemness,
had superior chondrogenic differentiation potential
compared to that of P5-MSC.
Fig. 1 Increased stemness of MSCs during continuous treatment with RSV. a Schematic overview of RSV treatment. b Morphological changes of
MSCs with passaging. Comparison between MSCs treated with RSV and without RSV (bar= 200 µm). c Proliferation, as determined on day 1, 2, 4, and
6. Expression levels of senescence markers, P16, P21, and P53 (d) and stemness markers, Nanog, Oct4 and Sox2 (e) in P1-MSC, P1-RMSC, P5-MSC, and
P5-RMSC, determined by western blotting. Quantitative analysis of protein expression levels of senescence (f) and stemenss (g) markers was
performed. Each dot represents a mean value of triplicate estimates with one donor and horizontal lines display the means and 95% CIs of the values
from different donors per group
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Inhibition of the hypertrophic maturation of RSV-treated
MSCs
During chondrogenic differentiation, hypertrophic
maturation inhibits hyaline cartilage regeneration19,41. To
determine whether P5-RMSC exhibited inhibited hyper-
trophic maturation during chondrogenic differentiation
in vitro, we evaluated the both mRNA and protein
expression levels of hypertrophic markers. P5-RMSC had
lower expression levels of hypertrophic markers than
those in P5-MSC (Fig. 4a, b). Additionally, an immuno-
cytochemical analysis demonstrated that the expression of
col10a1, a key marker of hypertrophic maturation, was
signiﬁcantly decreased in P5-RMSC (Fig. 4c). Con-
sequentially, sustained treatment of MSCs with RSV
enhanced the chondrogenic differentiation potential and
prevented hypertrophic maturation during in vitro
chondrogenic differentiation via improved stemness.
Increased cartilage regeneration potential in vivo
To determine whether continuous treatment of RSV on
MSCs could enhance the cartilage regeneration capacity
in vivo, we established a rabbit osteochondral defect
model (Fig. 5a). At 8 weeks post operation, we observed
the gross morphology of regenerated cartilage. In the
Hy/RMSC group, the surface of the defect site was almost
fully ﬁlled with cartilage-like tissue, along with nearby
cartilage. The Hy/RMSC group showed transparent
cartilage-like tissues, whereas the defect, Hy, and Hy/MSC
groups had incomplete cartilage tissue formation (Fig. 5b).
These results indicate that the regeneration of intact
cartilage surface tissues is possible via continuous treat-
ment of RSV on MSCs.
Histological analysis of regenerated cartilage in the rabbit
osteochondral defect model
We observed regenerated cartilage at defect sites by MT
and H&E staining. The MT stain showed higher collagen
deposition on cartilage surface of the Hy/RMSC group
compared to the Hy/MSC group (Fig. 6a). In the H&E
stain, the Hy/RMSC group had chondrocyte-like cells
with smooth cartilage-like tissues, which were similar in
morphology to normal cartilage. However, the defect, Hy,
and Hy/MSC groups showed ﬁbrous tissue formation
(Fig. 6b). Safranin O/Fast Green staining demonstrated
increased GAG formation in the Hy/RMSC group; the
Hy/MSC group showed slightly greater synthesis of GAG
than those of the other groups (Fig. 6c). Additionally,
O’Driscoll histological scoring was performed, and the
Hy/MSC group had a slightly higher score than those of
the defect or Hy group, and the Hy/RMSC group had a
signiﬁcantly higher score (Fig. 6d). These results demon-
strate that the Hy/MSC group had slight differences in
Fig. 2 Enhanced chondrogenic differentiation of P5-RMSC in vitro. a Relative expression levels of chondrogenic differentiation markers by real-
time PCR after chondrogenic differentiation on day 5. β-actin was used as an internal control. Western blotting was used to evaluate the
chondrogenic markers sox9, col2a1, and aggrecan (b) and a quantitative analysis of protein expression levels was performed (c). Each dot represents
a mean value of triplicate estimates with one donor and horizontal lines display the means and 95% CIs of the values from different donors per
group. P-values were calculated for comparisons with P5-MSC
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cartilage regeneration, but Hy/RMSC group exhibited
signiﬁcant differences in functional cartilage regeneration.
Effects of cartilage regeneration for RSV-treated MSCs
based on both chondrogenic and hypertrophic markers
Next, we evaluated the expression of extracellular
matrix (ECM) proteins, type II collagen and aggrecan, in
regenerated cartilage tissues by immunohistochemistry.
The Hy/RMSC group showed higher expression levels of
ECM proteins than those of the Hy/MSC group, which
exhibited slight expression of these proteins. A quantita-
tive analysis demonstrated that there was signiﬁcantly
higher expression of both type II collagen and aggrecan in
the Hy/RMSC group than in other groups (Fig. 7a, b).
Moreover, the expression of a hypertrophic marker, type
X collagen, was assessed. The Hy/RMSC group showed
very low expression of type X collagen, while other groups
had high expression levels. A quantitative analysis showed
that type X collagen expression was signiﬁcantly lower in
the Hy/RMSC group than in other groups (Fig. 7c). As a
result, the continuous treatment of MSCs with RSV
resulted in enhanced cartilage regeneration potential and
the inhibition of hypertrophic maturation, which limits
the use of MSCs for cell therapy19,41.
Fig. 3 Histological analysis of chondrogenic differentiation in vitro. a Safranin O and Alcian blue staining of micromass cultured MSCs on day 14
(bar= 200 µm). b, c Immunoﬂuorescence analyses of type II collagen and aggrecan, chondrogenic markers, were performed (upper) and results were
quantitatively analyzed (bottom) (bar= 100 µm). Each dot indicates a mean and 95% CI. P-values were calculated for comparisons with P5-MSC (n=
3, triplicates for each donor)
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Fig. 4 Inhibition of hypertrophic maturation during chondrogenic differentiation. a Relative expression levels of hypertrophic markers, as
determined by real-time PCR, after chondrogenic differentiation on day 21. b, c Hypertrophic markers were analyzed by western blotting on day 21
and quantitative analysis of protein expression levels was performed. d Immunoﬂuorescence analysis of col10a1, a hypertrophic maturation marker,
on day 21 (left) and quantiﬁcation of col10a1 expression (right) (bar= 100 µm). Each dot indicates a mean and 95% CI. P-values were calculated for
comparisons with P5-MSC (n= 3, triplicates for each donor)
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Discussion
In the present study, MSCs were continuously treated
with RSV from P0 to P5, and the maintenance of their
stemness was conﬁrmed. Continuous treatment main-
tained the activity of sirtuin 1 (SIRT1). P5-RMSC had
increased protein levels of stemness markers and
decreased levels of senescence markers compared with
those in P5-MSC. As shown in our previous study, the
maintenance of SIRT1 activity sustains the expression of
SOX237; thus, the stemness of MSCs could be maintained
over time.
P5-RMSC had similar stemness to that of P1-MSC and
improved chondrogenic differentiation potential (Figs. 2
and 3). Additionally, hypertrophic maturation was inhib-
ited in P5-RMSC, resulting in the increased expression of
type X collagen (COL10A1), matrix metalloproteinase 13
(MMP13), and alkaline phosphatase (ALP) (Fig. 4)19,41. To
conﬁrm the efﬁciency of the cartilage regenerative
potential of P5-RMSC, which had similar stemness to that
of P1-MSC, we established an osteochondral defect model
in rabbits with a depth of 3 mm and a diameter of 6 mm, a
critical size threshold for rabbit models42. This critical size
of osteochondral defect sites results in an inability to self-
heal. At 8 weeks post operation, P5-RMSC showed
smoother and more intact cartilage that was well attached
to nearby cartilage compared to other groups (Figs. 5 and
6). P5-RMSC had higher expression of ECM proteins
and lower expression of hypertrophic maturation markers
(Fig. 7). Therefore, P5-RMSC had increased cartilage
regeneration potential with hyaline-like tissue formation
in the rabbit osteochondral defect model when compared
with P5-MSC. These results demonstrate that our inno-
vative treatment method with RSV promotes the main-
tenance of stemness in MSCs over time and thus can
increase the cartilage regeneration potential (Fig. 8).
During long-term ex vivo expansion, MSCs do not grow
inﬁnitely, leading to senescence43. Bonab et al.17 demon-
strated that bone marrow-derived MSCs exhibit
Fig. 5 Regenerative potential of cartilage in a rabbit osteochondral defect model. a Establishment of the rabbit osteochondral defect model. A
total of 2 × 106 cells were applied to osteochondral defect sites (diameter, 6 mm; depth, 3 mm) with a hydrogel scaffold (n= 5). b Gross morphology
of osteochondral defect sites after 8 weeks
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Fig. 6 Histological examination of osteochondral defect sites. a, b Representative MT and H&E staining results for osteochondral defect sites of
each group at 8 weeks post operation. a Collagen deposition at osteochondral defect sites (upper; bar= 1 mm) and enlarged images to conﬁrm
collagen ﬁber alignment (bottom; bar= 500 µm). Blue area indicates newly formed collagen tissues. b H&E staining shows the cell morphology at
osteochondral defect sites (upper; bar= 1 mm, bottom; bar= 200 µm). c Safranin O/Fast Green staining indicates newly formed cartilage tissues (bar
= 2 mm). d Quantitative histological examination of regenerated cartilage at osteochondral defect sites. Three independent experts assessed the
regenerated cartilage tissues (n= 3). P-values were calculated for comparisons with the defect group
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decreased population doubling and shorter telomere
lengths as cells are subcultured. Furthermore, clinical
history, age, and genetic makeup determine the length of
the expansion period and quality of MSCs44. Thus,
retaining MSCs with sustained stemness is essential.
Several studies have demonstrated that long-term
exposure to RSV could increase the senescence of
MSCs34; during osteogenic differentiation, RSV adversely
affects adipogenic differentiation45. For the chondrogenic
differentiation of MSCs, previous studies have demon-
strated that treatment with RSV during the chondrogenic
differentiation period enhances chondrogenic potential
and inhibits inﬂammatory and degradative processes in
cartilage via the activation of SIRT146. Additionally, the
treatment of chondrocytes with RSV up-regulates SIRT1
expression, but leads to hypertrophic maturation47.
Unlike previous studies, our results showed that stemness
can be maintained in P5-MSC via continuous treatment
with RSV, thus maintaining their chondrogenic differ-
entiation potential. We also conﬁrmed the inhibition of
hypertrophic maturation both in vitro and in vivo. For
clinical applications, the recommended number of
Fig. 7 Immunoﬂuorescence analysis of chondrogenic and hypertrophic markers. Representative images of type II collagen (a) and aggrecan
(b), ECM proteins, in osteochondral defect sites (upper) and a quantitative analysis of chondrogenic marker expression (bottom). (c) Expression of
type X collagen, a hypertrophic marker, in osteochondral defect sites (left) and a quantitative analysis of type X collagen levels (right). P-values were
calculated for comparisons with the defect group (Bar= 200 µm)
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passages for MSCs is 3–548,49. In general, MSCs at pas-
sages 1–2 have high multipotency and MSCs at passages
4–5 have low multipotency and a loss of replicative
potential50,51. Accordingly, in our study, we continuously
treated MSCs with RSV from P0 to P5 to verify the sus-
tained stemness of MSCs at passage 5.
In our in vivo study, the defect group showed slight
regeneration of cartilage-like tissues (Fig. 6). Although the
osteochondral defect sizes were ﬁxed at 3 mm in depth,
during the surgical procedure, the bone marrow con-
centrates affected the regeneration of cartilage-like tissues
in the defect group. In fact, bone marrow concentrates
containing a variety of heterogenous cells and a lack of
MSCs are known to contribute to ﬁbrocartilage forma-
tion, rather than hyaline cartilage52. Thus, the bone
marrow concentrates did not affect the cartilage regen-
erative potential in the Hy/MSC and Hy/RMSC groups.
The Hy/RMSC group had hyaline-like cartilage tissue
formation (Figs. 6 and 7).
Taken together, the continuous treatment of RSV on
MSCs during in vitro cultivation resulted in sustained
stemness and chondrogenic differentiation potential, similar
to that of P1-MSC, thereby improving hyaline cartilage
regeneration (Fig. 8). Therefore, the novel treatment
method with RSV could provide a foundation for studies in
cell-based tissue engineering with minimal side effects.
Materials and methods
Isolation and identiﬁcation of MSCs from human bone
marrow aspirates
Bone marrow aspirates were acquired from the poster-
ior iliac crest of 10 healthy donors after obtaining
approval from the Institutional Review Board of Yonsei
University College of Medicine. MSCs were isolated and
cultivated as previously described53.
Chemical treatment of MSCs
Resveratrol (RSV; Sigma, St. Louis, MO, USA) was
dissolved in ethanol (EtOH) at 1 µM. RSV was con-
tinuously applied to MSCs from P0 to P5 (P5-RMSC) and
cells were subcultured as previously described54. MSCs
were evaluated up to P5 based on previous studies indi-
cating that MSCs at passages 3–5 are optimal for clinical
applications48,49.
In vitro chondrogenic differentiation of MSCs
For the chondrogenic differentiation of MSCs,
the micromass culture method was used, as previously
reported55. Brieﬂy, 10 µl of resuspended cells at a
density of 1 × 105 cells per well was added to the
center of the wells in 24-well plates. Cells were allowed
to attach for 2 h and chondrogenic medium was then
added. The chondrogenic medium was replenished every
3 days.
Quantitative real-time PCR (qRT-PCR)
Extraction of total RNA harvested from cells was per-
formed using TRIzol (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s protocols. To synthesize
cDNA, the Omniscript Reverse Transcription Kit (Qia-
gen, Hilden, Germany) was used for the reverse tran-
scription of 2 μg of RNA. To conduct real-time PCR,
2×qPCRBIO SyGreen Mix (PCR Biosystems, London, UK)
was used with 80 ng of cDNA. To quantify the relative
expression levels of target genes, beta-actin (β-actin) was
used as an internal control. Validated primers targeting
Sox9 (P232240), IHH (P101104), and ALP (P324388) were
used. Other primers were designed, as shown in Table 1,
and all primers were purchased from Bioneer (Daejeon,
Korea). Real-time PCR was performed using the ABI7900
(Applied Biosystems, Carlsbad, CA, USA) in accordance
with a previous report55.
Western blot analysis
Cell pellets were lysed and quantiﬁed as previously
reported56. The samples (10–30 μg of protein) were
separated by 10% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) (Sigma) and transferred
onto polyvinylidene diﬂuoride (PVDF) membranes
(Amersham Pharmacia, Escondido, CA, USA). Brieﬂy,
after blocking with 5% skim milk, membranes were
incubated with primary anti-SOX9 (1:3000, Millipore,
Billerica, MA, USA), anti-RUNX2, anti-P16 (1:3000,
Abcam, Cambridge, UK), anti-COL2A1, anti-AGGRE-
CAN, anti-OCT4, anti-MMP13, anti-COL1A1, anti-P21,
anti-P53 (1:500, Santa Cruz Biotechnology, Santa Cruz,
Fig. 8 Schematic illustration of the enhanced cartilage
regeneration potential in RSV-treated MSCs. Sustained treatment
of MSCs with RSV from P0 to P5 increased stemness and inhibited
senescence. With increased stemness, P5-RMSC had improved hyaline
cartilage regeneration potential
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CA, USA), anti-NANOG (1:1000, BD biosciences, San
Jose, CA, USA), anti-SOX2 (1:1000, Cell signaling Tech-
nology, Inc., Danver MA, USA), anti-HSP90 or anti-β-
ACTIN (1:1,000, Santa Cruz Biotechnology) overnight at
4 °C. Then, membranes were incubated with secondary
HRP-conjugated antibodies (1:5000, Santa Cruz Bio-
technology) for 1 h at room temperature.
Hydrogel precursor preparation
The hydrogel (Hy) was prepared as described pre-
viously57,58. In short, the cosolvent consisted of water and
dimethylformamide at a ratio of 3:2; it was supplemented
with 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
(EDC) and N-hydroxysuccinimide (NHS), which activates
3-(4-hydroxyphenyl)propionic acid (HPA), and this solu-
tion was added to a preheated gelatin solution. After 24 h
of reaction at 40 °C, the solution was dialyzed with deio-
nized water, ﬁltered, and lyophilized.
Animal experiments
Twenty New Zealand white rabbits (male, 3.5–4 kg; Doo
Yeol Biotech, Seocho-gu, Seoul, Korea) were used to
establish the osteochondral defect model according to
previously methods59. Brieﬂy, full-thickness cylindrical
osteochondral defect sites with a diameter of 6 mm
(3-mm depth) were formed on the surface of the femoral
patellar groove using the osteochondral autotransfer sys-
tem (OATS; Arthrex, Naples, FL, USA). For each osteo-
chondral defect site, the following treatments were
applied: None (defect), hydrogel only (Hy), Hy+ P5-MSC
(Hy/MSC), and Hy+ P5-RMSC (Hy/RMSC). A total of
2 × 106 in vitro cultured MSCs were mixed with the GH
polymer (5 wt%) that containing 0.0015mg/mL of horse-
radish peroxidase (HRP). The hydrogel formation was
occurred when the solution mixed with same volume of
GH polymer (5 wt%) that containing 0.005 wt% hydrogen
peroxide (H2O2)
60. At 8 weeks after the operation, the
rabbits were euthanized and defect sites were extracted
for the histological analysis. All animal experiments were
approved by the Committee on the Ethics of Animal
Experiments of Yonsei University College of Medicine
(Permit No. 2016-0200).
Histological evaluation
The samples obtained from osteochondral knee defects
and micromass pellets were ﬁxed for 7 days and 24 h in
10% formalin, respectively. After ﬁxation, the specimens
were embedded in parafﬁn and then parafﬁn sections
were deparafﬁnized, rehydrated, and washed with PBS.
The sections were stained with Masson’s trichrome (MT),
hematoxylin–eosin (H&E), Safranin O (SafO), and Alcian
blue (AB), as previously described59. The stained sections
were observed using a VS 120 virtual microscope
(Olympus, Tokyo, Japan). A quantitative analysis was
performed using ImageJ v.1.48 (Aspire Software Interna-
tional, Leesburg, VA, USA). Moreover, the O’Drsicoll
histological scoring system was used for the histological
assessment61, and the regenerated cartilage was assessed
by three blinded experts.
Immunocytochemistry
After washing parafﬁn sections with PBS, they were
incubated in hydrogen peroxidase for 10min to minimize
nonspeciﬁc background staining. To detect chondrogenic
markers, the sections were incubated with anti-COL2A1,
anti-AGGRECAN, and anti-COL10A1 (1:100, Santa Cruz
Biotechnology) antibodies at 4 °C for at least 12 h. The
attachment of secondary antibodies and ﬂuorescent
protein-conjugated secondary antibodies was performed
following previously described methods59. Nuclei were
stained with 4ʹ,6-diamidino-2-phenylindole (Sigma). An
inverted ﬂuorescence microscope (IX-71; Olympus,
Table 1 Primer sequences for real-time PCR
Target gene Forward sequence (5ʹ–3ʹ) Reverse sequence (5ʹ–3ʹ)
β-ACTIN GTCCTCTCCCAAGTCCACACAG GGGCACGAAGGCTCATCATTC
SOX5 AGCCCCACATAAAGCGTCCAAT GGTCCTCCTCCTCCTCATCGTA
SOX6 AGCAGAGCCTGTGAAGTCC GGTCCTCCTCCTCCTCATCGTA
COL2A1 GGCAATAGCAGGTTCACGTACA CGATAACAGTCTTGCCCCACTT
AGGRECAN CCTGGCCTGACATGGAGCTG GGACTGGGGGAGACCTCGAA
RUNX2 CCCAGTATGAGAGTAGGTGTCC GGGTAAGACTGGTCATAGGACC
OSTEOCALCIN AGCAAAGGTGCAGCCTTTGT CTTCACTACCTCGCTGCCCT
MMP13 GACGGGGTTTTGCCACACTG ATTGGGTGTGGTGGCTCACG
COL1A1 GCCCTGCTGGAGAGGAAGGA ATTGGGTGTGGTGGCTCACG
COL10A1 CCAGGACAGCCAGGCATCAA ATTGGGTGTGGTGGCTCACG
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Tokyo, Japan) was used to acquire images and expression
levels were quantiﬁed using ImageJ.
Statistical analysis
Each experiment was performed in triplicate using
samples from more than three donors. To detect differ-
ences between two groups, t-tests were used. The statis-
tical signiﬁcance of the differences among three or more
groups was evaluated using one-way analysis of variance
(ANOVA) with Tukey’s post hoc tests. All results
are presented as means and 95% CIs of the values from
three different donors per group.
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